Old Web
English
Sign In
Acemap
>
authorDetail
>
Kim Roos
Kim Roos
Sunnybrook Research Institute
Pembrolizumab
Oncology
Medicine
Internal medicine
DPX-Survivac
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study
2020
Blood
Neil L. Berinstein
Isabelle Bence-Bruckler
Nicholas Allen Forward
Pierre Laneuville
Joy Mangel
Douglas A. Stewart
Irina Amitai
Gail Klein
Nancy Pennell
Iran Rashedi
Kim Roos
Yogesh Bramhecha
Rebekah Conlon
Show All
Source
Cite
Save
Citations (1)
356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
2020
Journal for ImmunoTherapy of Cancer
Neil L. Berinstein
Isabelle Bence-Bruckler
Nick Forward
Pierre Laneuville
Joy Mangel
Douglas A. Stewart
Irina Amitai
Gail Klein
Nancy Pennell
Iran Rashedi
Kim Roos
Yogesh Bramhecha
Rebekah Conlon
Show All
Source
Cite
Save
Citations (0)
Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study
2019
Blood
Neil L. Berinstein
Isabelle Bence-Bruckler
Pierre Laneuville
Douglas A. Stewart
Nicholas Allen Forward
Liam Smyth
Gail Klein
Nancy Pennell
Kim Roos
Show All
Source
Cite
Save
Citations (1)
1